CLBS-12

N/A

Report date: 2023/01/12 15:51:46

Base Information

Drug NameCLBS-12

Drug Alias NameAutologous CD34+ cellsHONEDRACLBS-12

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy

Mechanisms of ActionCell replacementsHematopoietic progenitor cell antigen CD34 modulators

TargetsHematopoietic progenitor cell antigen CD34

Therapy Area/IndicationsIschemiaThromboangiitis ObliteransAtherosclerosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesCaladrius Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesLisata Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsIschemiaThromboangiitis ObliteransAtherosclerosis

Inactive IndicationsN/A

Other Information

ATC CodeN/A